Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report

BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Marrero, Santiago, Enjuanes, Cristina, Yun, Sergi, Comín-Colet, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/
https://www.ncbi.nlm.nih.gov/pubmed/32974448
http://dx.doi.org/10.1093/ehjcr/ytaa103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/
https://www.ncbi.nlm.nih.gov/pubmed/32974448
http://dx.doi.org/10.1093/ehjcr/ytaa103

Ejemplares similares